THE EFFECT OF THE GLUCAGON SUPPRESSORS PRAMLINTIDE AND EXENATIDE ON POSTPRANDIAL

胰高血糖素抑制剂普兰林肽和艾塞那肽对餐后的影响

• 批准号: 8356705
• 负责人: LUISA M RODRIGUEZ
• 金额: $ 1.42万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-12-01 至 2011-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8356705
• 关键词: Adult; Agonist; Child; Childhood; Clinical Research; Diabetes Mellitus; Dose; Funding; Glucagon; Glucose; Grant; Hyperglycemia; Incidence; Insulin; Laboratories; National Center for Research Resources; Non-Insulin-Dependent Diabetes Mellitus; Patients; Population; Pramlintide; Principal Investigator; Research; Research Infrastructure; Resources; Source; Testing; United States National Institutes of Health; analog; cost; exenatide; glucagon-like peptide 1; glycemic control; hyperglucagonemia; improved; islet amyloid polypeptide; macrovascular disease; prevent; receptor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. ABSTRACT The use of glucagon suppressors pramlintide and exenatide is well established in adult patients with T2DM, but there is a lack of information regarding an effective glucose lowering effect in pediatric T2DM. Previous studies from our laboratory showed that there is unabated early postprandial hyperglucagonemia in children with T2DM contributing to the marked postprandial hyperglycemia. There is insulin, amylin and GLP-1 deficiency in children with T2DM requiring insulin therapy. Both amylin and GLP-1 are potent endogenous glucagon suppressors. The glucose and glucagon lowering effect of the amylin analog pramlintide and the GLP-1 receptor agonist exenatide will be tested in insulin requiring children with T2DM. The lowest adult recommended doses would be used. With an increasing incidence of T2DM in the pediatric population, it is incumbent upon us to research new therapies in an effort to improve glycemic control and prevent the long-term micro and macrovascular complications associated with diabetes.

这个子项目是利用这些资源的众多研究子项目之一